DDIS-20. IMIPRIDONE STRUCTURE ACTIVITY RELATIONSHIP UNCOVERS ONC206 AS THE NEXT BITOPIC DRD2 ANTAGONIST FOR ONCOLOGY WITH DIFFERENTIATED RECEPTOR PHARMACOLOGY

ONC201 is the first bitopic antagonist of dopamine receptor D2 (DRD2) in oncology clinical trials, which have shown that the small molecule is well tolerated and induces durable tumor regressions in H3 K27M-mutant glioma patients. ONC201 possesses a unique tri-heterocyclic core structure that prompt...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Prabhu, Varun, Cuoco, Caroline, Jung, Jinkyu, Rahman Kawakibi, Abed, Willette, Blair, Day, Marilyn, Anantharaman, Lakshmi, Charter, Neil, Rucker, Joseph, Doranz, Benjamin, Oster, Wolfgang, Stogniew, Martin, Gilbert, Mark, Benjamin Free, R, Sibley, David, Allen, Joshua
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2019
Materias:
Drug Discovery
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6846870/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.271
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares